BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Alembic Pharmaceuticals Ltd. delivered a beat on earnings for Q2 FY21, led by strong traction in the Non-U.S./active pharmaceutical ingredient segment and a superior product mix.
India Domestic Formulations (DF) is back on the growth trajectory. The company also remains on track to start filing oncology injectables for the U.S. market in H2 FY21.
We raise our profit after tax estimate by 18% for FY21, factoring in superior performance in the Non-U.S./API segment and better margins.
We factor in increased opex for new facilities and hence maintain our profit after tax estimate for FY22.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR